CD4+ T lymphocytes mediate in vivo clearance of plasmid DNA vaccine antigen expression and potentiate CD8+ T-cell immune responses.
There is evidence that the limited immunogenicity of plasmid DNA vaccines is the result, at least in part, of the rapid clearance of vaccine antigen expression by antigen-specific immune responses. However, the cell types responsible for the clearance of plasmid DNA vaccine antigens are not known. Here we demonstrate that macrophages, NK cells, and CD8(+) T cells did not significantly contribute to the DNA antigen clearance but CD4(+) T cells played the crucial role in attenuating plasmid DNA vaccine antigen expression. Adoptive transfer experiments demonstrate that CD4(+) T cells facilitated DNA vaccine antigen clearance in a Fas/FasL-dependent manner. Furthermore, we show that depletion of CD4(+) T cells prevented the clearance of vaccine antigen and the appearance of a CD8(+) T-cell immune response. Inoculation of major histocompatibility complex class II KO mice with the plasmid DNA led to persistent antigen expression and abolition of a CD8(+) T-cell immune response. Importantly, the prolongation of antigen expression by disrupting the CD4(+) T-cell Fas/FasL myocytes signaling led to a 3- to 5-fold increase of antigen-specific CD8(+) T-cell responses. These data demonstrate a dominant role of CD4(+) T cell-mediated cytotoxicity in plasmid DNA vaccine antigen clearance.
Geiben-Lynn
Ralf
R
Division of Viral Pathogenesis, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. rgeibenl@bidmc.harvard.edu
Greenland
John R
JR
Frimpong-Boateng
Kwesi
K
van Rooijen
Nico
N
Hovav
Avi-Hai
AH
Letvin
Norman L
NL
D000818:Animals; D000941:Antigens / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000502:physiology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D018984:Epitopes, T-Lymphocyte / Q000378:metabolism; D053222:Fas Ligand Protein / Q000235:genetics; D007111:Immunity, Cellular / Q000276:immunology; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010957:Plasmids / Q000276:immunology / Q000378:metabolism; D019444:Vaccines, DNA / Q000378:metabolism*; D001613:beta 2-Microglobulin / Q000235:genetics; D019014:fas Receptor / Q000235:genetics
D000941:Antigens; D018984:Epitopes, T-Lymphocyte; D053222:Fas Ligand Protein; D019444:Vaccines, DNA; D001613:beta 2-Microglobulin; D019014:fas Receptor; D008156:Luciferases
J Virol. 2001 Dec;75(24):12161-8
11711607
Diabetes. 1994 Mar;43(3):505-9
8314025
J Immunol. 1992 Jul 15;149(2):661-7
1352532
J Immunol. 2004 May 15;172(10):6290-7
15128818
Eur J Immunol. 2006 Apr;36(4):875-86
16552712
J Immunol. 1991 Oct 1;147(7):2310-6
1918963
Mol Cell Biol. 1995 Feb;15(2):1060-70
7823921
J Parasitol. 1992 Aug;78(4):744-6
1386111
Gene Ther. 1997 Mar;4(3):181-8
9135731
Neurology. 1991 Jul;41(7):1128-32
1906147
Nat Med. 1996 Oct;2(10):1122-8
8837611
Ethics Behav. 1997;7(2):163-71
11655130
Nature. 1979 Mar 29;278(5703):451-3
313007
J Immunol. 1994 Feb 1;152(3):1127-33
7507960
J Immunol Methods. 1994 Sep 14;174(1-2):83-93
8083541
Mol Ther. 2005 Jul;12(1):164-70
15963932
Blood. 1974 Feb;43(2):201-6
4589319
J Virol. 2007 Jan;81(1):74-83
17050608
Scand J Immunol. 1976 Jun;Suppl 5:23-30
1052388
J Exp Med. 1975 Nov 1;142(5):1231-40
53260
J Immunol. 2007 May 1;178(9):5652-8
17442948
Immunol Rev. 1995 Aug;146:57-79
7493761
Immunol Cell Biol. 1990 Aug;68 ( Pt 4):235-41
2123472
Arthritis Rheum. 1999 Feb;42(2):291-8
10025923
Am J Physiol Regul Integr Comp Physiol. 2006 Jun;290(6):R1488-95
16424086
Vaccine. 1997 Apr;15(5):553-60
9160524
Eur J Immunol. 2001 Jan;31(1):301-10
11265647
J Intern Med. 2003 Apr;253(4):402-10
12653868
Nat Genet. 1996 Jul;13(3):303-8
8673129